Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gastric cancer: Translating novels concepts into clinical practice.
Salati M, Orsi G, Smyth E, Aprile G, Beretta G, De Vita F, Di Bartolomeo M, Fanotto V, Lonardi S, Morano F, Pietrantonio F, Pinto C, Rimassa L, Vasile E, Vivaldi C, Zaniboni A, Ziranu P, Cascinu S. Salati M, et al. Among authors: vasile e. Cancer Treat Rev. 2019 Sep;79:101889. doi: 10.1016/j.ctrv.2019.101889. Epub 2019 Aug 14. Cancer Treat Rev. 2019. PMID: 31445415 Review.
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Loupakis F, Masi G, Fornaro L, Vasile E, Allegrini G, Fontana E, Granetto C, Salvatore L, Mentuccia L, Andreuccetti M, Cortesi E, Merlano M, Cascinu S, Falcone A. Loupakis F, et al. Among authors: vasile e. Cancer Chemother Pharmacol. 2010 Aug;66(3):559-66. doi: 10.1007/s00280-009-1196-1. Epub 2010 Mar 17. Cancer Chemother Pharmacol. 2010. PMID: 20237927 Clinical Trial.
Anti-HER agents in gastric cancer: from bench to bedside.
Fornaro L, Lucchesi M, Caparello C, Vasile E, Caponi S, Ginocchi L, Masi G, Falcone A. Fornaro L, et al. Among authors: vasile e. Nat Rev Gastroenterol Hepatol. 2011 Jun 7;8(7):369-83. doi: 10.1038/nrgastro.2011.81. Nat Rev Gastroenterol Hepatol. 2011. PMID: 21647199 Review.
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.
Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Vivaldi C, Belli C, Bergamo F, Lutrino SE, Filippi R, Russano M, Vaccaro V, Brunetti AE, Rotella V, Falcone A, Barbera MA, Corbelli J, Fasola G, Aglietta M, Zagonel V, Reni M, Vasile E, Brandi G. Fornaro L, et al. Among authors: vasile e. Br J Cancer. 2014 Apr 29;110(9):2165-9. doi: 10.1038/bjc.2014.190. Epub 2014 Apr 8. Br J Cancer. 2014. PMID: 24714745 Free PMC article.
Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma.
Cereda S, Milella M, Cordio S, Leone F, Aprile G, Galiano A, Mosconi S, Vasile E, Santini D, Belli C, Auriemma A, Novarino A, Vaccaro V, Martines C, Marino D, Lutrino SE, Palazzo V, Reinach B, Aldrighetti L, Reni M. Cereda S, et al. Among authors: vasile e. Cancer Chemother Pharmacol. 2016 Jan;77(1):109-14. doi: 10.1007/s00280-015-2919-0. Epub 2015 Dec 10. Cancer Chemother Pharmacol. 2016. PMID: 26659366 Clinical Trial.
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data.
Fornaro L, Vivaldi C, Cereda S, Leone F, Aprile G, Lonardi S, Silvestris N, Santini D, Milella M, Caparello C, Musettini G, Pasquini G, Falcone A, Brandi G, Sperduti I, Vasile E; GICO group (Gruppo Italiano COlangiocarcinoma). Fornaro L, et al. Among authors: vasile e. J Exp Clin Cancer Res. 2015 Dec 23;34:156. doi: 10.1186/s13046-015-0267-x. J Exp Clin Cancer Res. 2015. PMID: 26693938 Free PMC article.
235 results